glp 1 super bowl ad 📺 commercials this year featured GLP-1 weight-loss drugs and celebrities like Serena Williams, bringing these medications into the national spotlight. 🧠 The ads have drawn attention to broader conversations around Serena Williams just did a

Description

Some Ozempic and GLP-1 users report feeling emotionally flat or

The GLP-1 drugs market size is predicted to grow from USD 58.05 billion in 2026 to USD 132.79 billion by 2035, driven by a CAGR of 9.63%.

The Phase 3 ATTAIN-1 trial had good results that led to this approval, but not all positive: 12.4% average weight loss (27.3 lbs) at highest dose Lower than the 15-20% weight loss seen with injectables Wegovy and Zepbound Nearly 1/4 of participants on the highest dose reported vomiting Vomiting rates are much higher than injectable GLP-1s However, there is likely a niche for Foundayo (along with the pill version of Wegovy) due to convenience: No refrigeration requirements or injection site reactions Eliminates barriers for patients avoiding injectables due to stigma, needle aversion, or storage constraints It's possible we could see this as a "maintenance" therapy after an initial injectable course

Find your exact daily protein target based on your weight, medication and activity level

GLP-1 weight loss therapy is now accessible without insurance coverage through compounded medications priced from $129 monthly at PlexusDx, eliminating the need for prior authorizations or membership commitments